SCHEMBL5752117

SCHEMBL5752117

CC(=O)CC(=O)O[C@H]1CC(=O)N(Cc2ccccc2)C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
GAA P10253 3/20 0.50
HPGD P15428 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
STAT6 P42226 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
POLB P06746 1/20 0.47
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
MT-CO2 P00403 2/20 0.43
ALOX5 P09917 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9636719 0.87 ALDH1A1 (0.55) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL3593084 0.87 ALDH1A1 (0.55) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL28431888 0.82 ALDH1A1 (0.55) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL18009424 0.81 ALDH1A1 (0.53) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL18009314 0.81 ALDH1A1 (0.53) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL18009426 0.81 ALDH1A1 (0.53) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL18009317 0.81 ALDH1A1 (0.48) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL18009304 0.81 ALDH1A1 (0.48) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL18009224 0.81 ALDH1A1 (0.48) ALDH1A1GAAHPGDCYP1A2CYP3A4
SCHEMBL2273021 0.80 ALDH1A1 (0.47) ALDH1A1GAAHPGDCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0716081-B1 Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives BAYER HEALTHCARE AG (DE) 2006-04-05 EP disclosed
EP-0716081-B1 Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives BAYER HEALTHCARE AG (DE) 2006-04-05 EP disclosed
EP-1443043-A2 Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives Bayer HealthCare AG (DE) 2004-08-04 EP disclosed
US-RE36607-E Pyrrolidine compounds and process of preparing BAYER AKTIENGESELLSCHAFT (DE) 2000-03-07 US disclosed
US-5910593-A Highly selective process for the preparation of enantiomerically pure phenylsubstituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives BAYER AKTIENGESELLSCHAFT (DE) 1999-06-08 US disclosed
US-5849924-A Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives BAYER AKTIENGESELLSCAHFT (DE) 1998-12-15 US disclosed
US-5700948-A CALCIUM ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 1997-12-23 US disclosed
EP-0716081-A1 Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives BAYER AG (DE) 1996-06-12 EP disclosed